KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.80

Mediators of Filgotinib Treatment Effects in Ulcerative Colitis: Exploring Circulating Biomarkers in the Phase 2b/3 SELECTION Study.

Hiroshi Nakase, Silvio Danese, Walter Reinisch, Timothy Ritter, Yan Liang, Emily Wendt, Barrett G Levesque, Oh Kyu Yoon, Yuan Tian, Luting Zhuo, Emmanuel Karouzakis, Yasmina Bauer, Alessandra Oortwijn, Toshihiko Kaise, Vladislav A Malkov, Toshifumi Hibi

Inflamm Bowel Dis 31(4) 1095-1108

PMID39656830
PMCIDPMC11985404
DOI10.1093/ibd/izae278
发表日期2024-12-10
入排依据:The study is a randomized controlled Phase 2b/3 trial (SELECTION study) involving human participants, but the disease is ulcerative colitis, which is not oncology. Therefore, it does not meet the oncology eligibility criteria.
摘要

摘要

BACKGROUND: We utilized patient samples from the large, phase 2b/3 SELECTION trial to identify circulating biomarkers of ulcerative colitis (UC) and potential early mediators of filgotinib treatment effects. METHODS: Samples were collected at baseline and during the induction phase of the SELECTION trial. Evaluated biomarkers comprised serum and stool proteins (measured by enzyme-linked immunosorbent assay), whole-blood cell counts, and whole-blood RNA-seq-derived gene-expression factors identified via exploratory factor analysis. Biomarker levels were assessed by baseline disease severity (endoscopy/bleeding/stool and Mayo Clinic Score) and biologic status (naive vs experienced). Effects of filgotinib on biomarker levels, including week 4 biomarker changes that may mediate week 10 clinical improvements, were assessed. RESULTS: The biomarker analysis set included 598 biologic-naive patients and 592 biologic-experienced patients. Systemic inflammatory biomarkers (C-reactive protein [CRP], interleukin-6 [IL-6], serum amyloid A [SAA], and platelet cell counts) had the strongest positive correlations with baseline UC disease severity. CRP, IL-6, SAA, and neutrophil activation biomarkers (including neutrophil gelatinase-associated lipocalin [NGAL], tumor necrosis factor ɑ, and oncostatin M [OSM]), as well as platelet, neutrophil, and monocyte cell counts were increased in biologic-experienced versus biologic-naive patients. Gene-expression-derived plasmablast and cell proliferation factors were positively correlated with disease severity; B cell, T-cell activation, and plasmacytoid dendritic cell factors were negatively correlated. Filgotinib reduced nearly all proinflammatory biomarkers correlated with baseline UC disease activity; reduced SAA, CRP, IL-6, NGAL, and OSM at week 4 were identified as mediators of improved week 10 clinical scores. CONCLUSIONS: Filgotinib significantly impacted circulating biomarkers related to UC pathology. Several proinflammatory and neutrophil activation biomarkers may be early mediators of filgotinib treatment effects. CLINICALTRIALS.GOV IDENTIFIER: NCT02914522.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。